- Home
- RPTX
as 01-24-2025 4:00pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 54.4M | IPO Year: | 2020 |
| Target Price: | $7.00 | AVG Volume (30 days): | 476.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $8.49 | Next Earning Date: | 02-26-2025 |
| Revenue: | $66,524,000 | Revenue Growth: | 18.19% |
| Revenue Growth (this year): | 11.8% | Revenue Growth (next year): | -88.02% |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks
5 days ago
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MT Newswires
16 days ago
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Business Wire
16 days ago
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
MT Newswires
a month ago
Top Midday Decliners
Benzinga
a month ago
Why Is Repare Therapeutics Stock Trading Lower On Friday?
GuruFocus.com
a month ago
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results
Clinical Trials Arena
a month ago
Repare Therapeutics eyes Phase III cancer study after Mythic trial success
Compare RPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.